[Heavyweight] Chia Tai Tianqing will win the first copy of Lenvatinib

Recently, Chia Tai Tianqing Pharmaceutical Group entered the administrative examination and approval stage with generic 4 types of lenvatinib mesylate capsules.

Lenvatinib is an oral multi-target kinase inhibitor developed by Eisai, which can inhibit vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived Growth factor receptor (PDGFR) α, RET and KIT and other targets.

Lenvatinib mesylate capsule was approved for marketing in China in September 2018.

According to data from Meinenet, in 2019, the total sales of lentinib in Chinese urban public hospitals, county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies exceeded 300 million yuan.

Registration application status of Lenvatinib mesylate capsules

Source: One-click search on Mi Nei.

At present, a total of 10 companies in the domestic market have submitted 4 types of listing applications for lenvatinib mesylate capsules, involving Chia Tai Tianqing, Simcere Pharmaceuticals, Qilu Pharmaceuticals, Kelun Pharmaceuticals, CSPC, Yangzijiang Pharmaceuticals and Osaikang Wait.

Source: Minet database